flavonoids / Warburg Cancer Research Results

Flavonoids — a large class of plant polyphenols (natural products) including flavonols (quercetin, kaempferol), flavones (apigenin, luteolin), flavanones (naringenin), isoflavones (genistein), flavan-3-ols (EGCG/catechins), and anthocyanins. Sources: fruits/berries, tea/cocoa, legumes, herbs, and standardized extracts.

Primary mechanisms (conceptual rank):
1) Redox signaling modulation (often hormetic: low-dose NRF2 ↑; high-dose ROS ↑ in cancer)
2) Anti-inflammatory transcription suppression (NF-κB ↓; cytokines ↓)
3) Kinase signaling modulation (PI3K/AKT/mTOR ↓; MAPK context-dependent)
4) Mitochondrial stress → apoptosis (cancer; often high concentration only)
5) Iron/copper chelation + lipid-peroxidation effects (ferroptosis overlap in select contexts)

Bioavailability / PK relevance: Many flavonoids have low oral bioavailability (rapid phase II conjugation: glucuronidation/sulfation; microbiome-derived metabolites). Plasma free aglycone levels are typically low; tissue effects often reflect metabolites and chronic exposure.

In-vitro vs oral exposure: Many “anti-cancer” cytotoxic effects occur at micromolar aglycone concentrations exceeding typical systemic exposure from diet/supplements (high concentration only), unless specialized formulations or local GI exposure is the intent.

Clinical evidence status: Broad epidemiology + small human trials for cardiometabolic/inflammatory endpoints; oncology evidence mostly preclinical/adjunct-hypothesis; no class-wide RCT oncology approval.

Flavonoids — a structurally diverse superfamily of plant-derived polyphenolic secondary metabolites characterized broadly by a C6–C3–C6 carbon framework. They are a phytochemical class rather than a single drug or uniform therapeutic modality. Standard abbreviations include flavonoids and Flav; individual subclasses require separate names. Major dietary subclasses are flavonols, flavones, flavanones, flavan-3-ols, anthocyanins and isoflavones; chalcones are also commonly included in the broader flavonoid family. Representative compounds include quercetin, kaempferol, fisetin, apigenin, luteolin, naringenin, hesperetin, catechin, epicatechin, EGCG, cyanidin, genistein and daidzein. Principal sources include fruits, berries, tea, cocoa, citrus, legumes, herbs and vegetables. Because flavonoids differ markedly in structure, metabolism and target selectivity, class-level statements describe recurring patterns rather than effects shared uniformly by every compound.

Primary mechanisms (ranked):

1. Redox-signaling modulation, typically involving antioxidant and NRF2-linked cytoprotection at physiologic exposure but mitochondrial ROS elevation and oxidative injury in some cancer models at higher concentrations.
2. Suppression of inflammatory transcriptional programs, particularly NF-κB-associated cytokine, COX-2 and inducible inflammatory signaling.
3. Inhibition of proliferative and survival signaling through PI3K/AKT/mTOR, receptor tyrosine kinase, STAT3 and ERK pathways in compound-dependent cancer models.
4. Induction of mitochondrial dysfunction, altered BCL-2-family balance, cytochrome-c release and caspase-mediated apoptosis.
5. Cell-cycle arrest through modulation of cyclins, CDKs, p21, p27, p53 and related checkpoint machinery.
6. Suppression of angiogenesis, epithelial–mesenchymal transition, invasion and metastasis through HIF-1α, VEGF, β-catenin, matrix metalloproteinase and adhesion-related pathways.
7. Metabolic modulation involving glucose transport, glycolysis, HK2, PKM2, HIF-1α and AMPK signaling in selected compounds and models.
8. Modulation of iron handling and lipid peroxidation; flavonoids may inhibit or promote ferroptosis depending on their chelating, radical-scavenging and pro-oxidant properties.
9. Chemosensitization or radiosensitization through suppression of survival signaling, DNA-repair responses, drug-efflux mechanisms or antioxidant defenses in selected experimental systems.

Bioavailability / PK relevance: Oral pharmacokinetics vary substantially by subclass, glycosylation pattern, food matrix and intestinal microbiota. Most absorbed flavonoids undergo extensive intestinal and hepatic glucuronidation, sulfation and methylation, while unabsorbed material is converted by the microbiome into smaller phenolic metabolites. Circulating exposure therefore consists predominantly of conjugated and microbial metabolites rather than the free aglycones commonly used in laboratory experiments. Certain flavonoids can also affect drug transporters or CYP-mediated metabolism, but the clinical significance is compound-, dose- and medication-dependent.

In-vitro vs systemic exposure relevance: Many anticancer experiments use approximately 10–100 µM free aglycone, whereas normal dietary intake commonly produces much lower concentrations of unconjugated parent compound in plasma. Consequently, direct kinase inhibition, mitochondrial toxicity, apoptosis and ferroptosis observed at high micromolar concentrations may not be systemically achievable through ordinary foods or conventional supplements. Gastrointestinal tissues, concentrated formulations and pharmacologically developed derivatives may experience different exposure conditions.

Clinical evidence status: Human evidence is strongest for dietary patterns or standardized flavonoid-rich foods affecting vascular, cardiometabolic and selected cognitive endpoints. Cancer-prevention evidence is primarily observational and subclass-specific, while cancer-treatment evidence remains predominantly preclinical with limited early-phase or adjunct studies involving individual flavonoids. Flavonoids are not approved as a class for treating cancer or Alzheimer’s disease, and class-wide efficacy cannot be inferred from results obtained with one constituent.

Flavonoid Mechanistic Profile

TSF: P: 0–30 min    R: 30 min–3 hr    G: >3 hr

Flavonoids and Alzheimer’s disease — dietary flavonoids and flavonoid-rich foods are investigated as supportive neurovascular and neuroprotective exposures rather than established Alzheimer’s disease therapies. The most defensible class-level mechanisms are attenuation of oxidative and inflammatory stress, enhancement of endothelial function and cerebral perfusion, and chronic modulation of synaptic-plasticity signaling. Effects on amyloid-β aggregation, amyloid processing, tau phosphorylation and clearance are primarily preclinical and vary markedly among compounds.

Primary mechanisms (ranked):

1. Reduction of oxidative stress and lipid peroxidation through direct and metabolite-mediated redox effects and adaptive NRF2 signaling.
2. Suppression of microglial and astrocytic inflammatory signaling, including NF-κB and pro-inflammatory cytokine programs.
3. Support of cerebrovascular endothelial function, nitric-oxide signaling and neurovascular coupling.
4. Enhancement of BDNF, CREB, ERK and related synaptic-plasticity pathways during sustained exposure.
5. Preservation of mitochondrial function and cellular energy homeostasis.
6. Secondary modulation of amyloid-β production, aggregation or toxicity and tau-associated signaling in selected preclinical models.

Bioavailability / PK relevance: Brain exposure is likely mediated largely by circulating conjugates, microbiome-derived phenolic metabolites and indirect vascular or peripheral signaling rather than sustained high concentrations of free parent flavonoids. Blood–brain barrier penetration differs considerably among compounds and metabolites.

Clinical evidence status: Observational cohorts associate higher flavonoid intake with slower cognitive decline or reduced dementia risk, and some randomized trials of cocoa flavanols, berries or anthocyanin-rich interventions report modest cognitive or vascular benefits. Results are heterogeneous, and biomarker-confirmed Alzheimer’s disease modification has not been established.

Alzheimer’s Disease Mechanistic Profile

TSF: P: 0–30 min    R: 30 min–3 hr    G: >3 hr